Select Language
Transferrin R
Transferrin R Overview
| English Name | Transferrin receptor protein 1 | Approved Drugs | 1 |
| Drugs in Clinical Trials | 12 | Target Synonym | TFRC，T9，sTfR，Transferrin receptor protein 1，TR，Transferrin Receptor，P90，Transferrin Receptor (P90， CD71)，CD71 Antigen，IMD46，CD71，TfR1，Trfr，TfR |
| Highest Development Stage | Approved | ||
| English Name | Transferrin receptor protein 1 |
| Target Synonym | TFRC，T9，sTfR，Transferrin receptor protein 1，TR，Transferrin Receptor，P90，Transferrin Receptor (P90， CD71)，CD71 Antigen，IMD46，CD71，TfR1，Trfr，TfR |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 12 |
| Highest Development Stage | Approved |
Transferrin R Product List
- Product Category
Protein (16)Cell (1)
- Product Status
Launched (17)
- Species
Human (7)Cynomolgus (4)Mouse (4)Rat (2)
- Tag
His Tag (7)His Tag & Avi Tag (4)Fc Tag (3)Tag Free (2)Fc Tag & Avi Tag (1)
- Conjugate
Unconjugated (8)Biotin-labeled (8)- (1)
Add to Cart
Total: 17
- 1
- 2
Transferrin R Background
CD antigen CD71 is also known as Transferrin receptor protein 1, TfR, sTfR, p90, TfR1, Trfr, which belongs to the peptidase M28 family and M28B subfamily. CD71 /TFR contains one PA (protease associated) domain. CD71 / TfR1 is required for iron delivery from transferrin to cells. CD71 is a potential new target in cases of human leukomia & lymphoma. CD71 /TFRC / TfR has been shown to interact with GABARAP and HFE.
Transferrin R Synonyms
CD71,TFRC,TFR,sTfR,TfR1,Trfr,T9,p90
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Human apotransferrin (Sanquin Blood Supply Foundation) | Phase 3 Clinical | Sanquin Plasma Products Bv | Iron Metabolism Disorders; beta-Thalassemia | Details | |
| Delpacibart eteddesiran | AOC-1001; AOC 1001 | Phase 3 Clinical | Avidity Biosciences Inc | Myotonic Disorders; Genetic Diseases, Inborn; Musculoskeletal Diseases; Muscular Disorders, Atrophic; Myotonic Dystrophy; Muscular Atrophy; Heredodegenerative Disorders, Nervous System; Muscular Diseases; Neuromuscular Diseases; Nervous System Diseases; Muscular Dystrophies; Neurodegenerative Diseases; Myotonia | Details |
| CX-2029 | ABBV-2029; ABBV-CX-2029; CX-2029 | Phase 2 Clinical | Abbvie Inc, Cytomx Therapeutics Inc | Solid tumours; Head and Neck Neoplasms; Esophageal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Non-Small-Cell Lung | Details |
| DYNE-251 | DYNE251 | Phase 2 Clinical | Dyne Therapeutics Inc | Muscular Dystrophy, Duchenne | Details |
| JR-446 | JR-446 | Phase 2 Clinical | Jcr Pharmaceuticals Co Ltd, Medipal Holdings Corp | Mucopolysaccharidosis III | Details |
| JR-441 | JR-441 | Phase 2 Clinical | Jcr Pharmaceuticals Co Ltd | Mucopolysaccharidosis III | Details |
| Lepunafusp alfa | JR-171 | Phase 2 Clinical | Jcr Pharmaceuticals Co Ltd | Mucopolysaccharidosis I | Details |
| PPMX-T003 | PPMX-T003 | Phase 2 Clinical | Perseus Proteomics Inc | Leukemia; Polycythemia Vera | Details |
| Trontinemab | RO-7126209; RG-6102 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Alzheimer Disease | Details |
| INA-03 | INA03 | Phase 1 Clinical | Inatherys | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
| KK-2260 | KK2260; KK-2260 | Phase 1 Clinical | Kyowa Kirin Co Ltd | Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| ABX-1100 | ABX-1100 | Phase 1 Clinical | Aro Biotherapeutics Co | Glycogen Storage Disease Type II | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Pabinafusp alfa | JR-141 | Approved | Jcr Pharmaceuticals Co Ltd | Japan | Mucopolysaccharidosis II | Jcr Pharmaceuticals Co Ltd | 2021-03-23 | Mucopolysaccharidosis II | Details |
Product Reviews
ZZ2022-10-11
0People LikeWe needed this product for our antibody research. ACRO managed to get it to us much faster than we expected, which made our research work very accurate. cd71 is a potential new target in human leukemia and lymphoma cases. cd71 /TFRC / TfR has been shown to interact with GABARAP and HFE. I am very pleased with the product and the quick technical support.- C***U2022-10-06 0People LikeThis product was needed for our antibody research. ACRO managed to deliver this much quicker than we expected which made the conduct of our research extremely accurate. CD71 is a potential new target in cases of human leukomia & lymphoma. CD71 /TFRC / TfR has been shown to interact with GABARAP and HFE. We really satisfied this product, and we absolutely order more products for our further projects. _x000D_ _x000D_
- Y***n2022-04-15 0People LikeThis is the first active mouse CD71 ECD in the market. Nothing is better than this since everything else is pretty dead._x000D_ Took a little longer to receive but it was worth the time!!!
Load More
- Overview
- Product List
- Marketed Drug Information
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland